Multicenter phase 2 trial of isatuximab, carfilzomib, lenalidomide, and dexamethasone for high-risk newly diagnosed multiple myeloma
Prof. Katja Weisel
The multicenter phase 2 GMMG-CONCEPT trial in Germany investigated isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) for the difficult-to-treat group or high-risk newly diagnosed multiple myeloma (HRNDMM). The regimen induced high rates of sustainable minimal residual disease (MRD) negativity, both among the transplant-eligible (TE) and among the transplant-ineligible (TNE) patients. Median progression-free survival was not reached with a median follow-up of 44 and 33 months in the TE and TNE groups, respectively.
